Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773204 | 0.87 | NR4A3 (0.78) | NR4A3ALDH1A1POLBMAPK1MAPK14 | |
| SCHEMBL2079637 | 0.86 | NR4A3 (0.59) | NR4A3ALDH1A1POLBMAPK1MAPK14 | |
| SCHEMBL15779573 | 0.85 | ALDH1A1 (0.55) | ALDH1A1POLBMAPK1MAPK14MAPT | |
| SCHEMBL14097123 | 0.80 | MAPT (0.78) | ALDH1A1POLBMAPK1MAPK14MAPT | |
| SCHEMBL4485719 | 0.79 | NR4A3 (0.54) | NR4A3ALDH1A1POLBMAPK1MAPK14 | |
| SCHEMBL1074233 | 0.78 | MAPK1 (0.58) | NR4A3ALDH1A1POLBMAPK1MAPK14 | |
| SCHEMBL13593554 | 0.77 | ALDH1A1 (0.63) | NR4A3ALDH1A1POLBMAPK1MAPK14 | |
| SCHEMBL15779332 | 0.77 | MAPT (0.49) | ALDH1A1POLBMAPK1MAPK14MAPT | |
| SCHEMBL27808 | 0.76 | NR4A3 (0.61) | NR4A3ALDH1A1POLBMAPK1MAPK14 | |
| SCHEMBL10813419 | 0.76 | RAB9A (0.46) | NR4A3ALDH1A1POLBMAPK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2928474-B1 | DIAZOLE LACTAMS | CHEMOCENTRYX INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20160303084-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303084-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303084-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9328116-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328116-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140171420-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171420-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171420-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014089495-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089495-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303084-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | NR4A3 458/4885ALDH1A1 923/4885POLB 3383/4885 |
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | NR4A3 37/4885ALDH1A1 2159/4885POLB 2936/4885 |
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | NR4A3 458/4885ALDH1A1 923/4885POLB 3383/4885 |
| US-20140171420-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | NR4A3 458/4885ALDH1A1 923/4885POLB 3383/4885 |
| US-10744118-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | NR4A3 458/4885ALDH1A1 923/4885POLB 3383/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | NR4A3 458/4885ALDH1A1 923/4885POLB 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.